AZN.US Weekly Report · 2026-W29
Period: July 13 - 18, 2026
AstraZeneca’s stock price stabilized this week following a clinical trial setback early in the period, closing at USD 168.9 with a weekly decline of 1.58%. Despite an initial 6% decline, the company’s valuation remains at historically depressed levels and institutional ratings remain constructive. However, net outflows of large-cap funds clash with positive institutional sentiment, presenting a mixed signal requiring careful monitoring.
Market Performance
AZN opened at USD 168.15 (Monday) and closed at USD 168.9 at week’s end, down 1.58% from the prior week’s final trading day (July 10, USD 171.61). Intra-week range was USD 3.16 (170.31-167.15), turnover rate 0.13%, and trading volume 1.98 million shares, consistent with 60-day median levels with no abnormal volume spikes.
The critical event occurred on July 9, with a 6.5% decline (189.28 to 178.49), marking the week’s low point. The decline extended on July 10 with additional weakness. The pattern is characterized as “breakout downtrend followed by consolidation on lower volume”—recovery above the weekly low will be a key observation point for the coming week.
Valuation and Earnings
AstraZeneca trades at a P/E of 25.21x, which falls at the 6.7th percentile of the 5-year valuation range—a historically depressed level. This indicates the stock trades cheaper than approximately 93.3% of trading days over the past five years. Industry median is reported as -1.27 (data anomaly, not comparable), though the company ranks 43 out of 255 in the pharma sector, placing it in the mid-to-upper tier relatively.
Q1 2026 results showed EPS of USD 1.97, up 5.35% year-over-year but down sequentially from Q4 2025’s USD 1.48. Operating revenue reached USD 15.288 billion (YoY +12.51%), while net profit grew just 5.62%—a divergence between top-line and bottom-line growth rates. The net profit margin compressed to 20.15% from prior quarter’s levels.
Consensus EPS forecast stands at USD 7.92-8.42 (latest snapshot USD 7.92), representing an 18% premium to TTM EPS of USD 6.70. This spread reflects market expectations for earnings acceleration over the next nine months.
Capital Flows
July 17 data shows large-cap net outflows of USD 317.94 million (inflows USD 150.99, outflows USD 468.93). Mid-cap showed net inflows of USD 141 million. Retail flow was mixed with small-cap showing net outflows of approximately USD 161.53 million. The pattern reflects simultaneous large and retail fund exit, consistent with the early-week decline intensity.
Large fund outflows likely indicate either risk aversion toward near-term trial developments or profit-taking rebalancing. The synchronized exit by both large and retail participants suggests broad reassessment of the risk-reward setup.
Institutional Views
AstraZeneca holds 10 analyst ratings: 6 strong buys, 2 buys, and 2 outperforms. This rating distribution ranks 38th among 255 pharma companies. The aggregate recommendation is “buy” with a target price of USD 213.89, implying 26.6% upside from current levels.
These ratings carry publication lag relative to this week’s events. Most were updated prior to July 17 and likely predate the trial setback communication, suggesting rating revisions may follow in coming sessions.
This Week’s News
Three themes dominated news flow:
Product and Partnerships: AstraZeneca agreed to pay up to USD 1.5 billion to license Zegfrovy for lung cancer from Dizal Pharma, underscoring continued oncology focus. Under its CSPC Pharma collaboration, the company also paid a USD 25 million R&D milestone.
Trial Progress: The ATTR-CM (cardiac amyloidosis) trial conducted with Ionis Pharmaceuticals missed its primary endpoint—the direct trigger for the early-week selloff. Ionis absorbed a larger market impact, with AstraZeneca affected as a partner.
Rating Actions: Deutsche Bank initiated a sell rating citing uncertainty. HSBC downgraded from buy to hold citing trial disappointments and lack of near-term catalysts. Conversely, JPMorgan, Citi, Jefferies, and Berenberg reiterated or maintained buy ratings.
Related Links:
- AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug
- Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
- AstraZeneca falls 6% in regular trading after trial misses endpoint
- AstraZeneca (AZN) Gets a Sell from Deutsche Bank
- HSBC Cuts AstraZeneca to Hold Amid Trial Setbacks and Uncertain Catalysts
- J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
- AstraZeneca (AZN) Receives a Buy from Citi
- Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
- Berenberg Bank Sticks to Its Buy Rating for AstraZeneca (AZN)
- AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
Contradiction and Consistency
This week presents conflicting signals:
The Contradiction: Depressed valuation (P/E at 6.7th percentile) + constructive institutional sentiment (6 of 10 strong buys) versus synchronized capital outflows. This suggests institutional ratings lag the market’s risk reassessment following trial results, reducing their near-term relevance.
Consistent Signals: Decelerating EPS growth (YoY just 5.35%) + operating income growth lagging revenue growth + trial risk all point toward rising earnings uncertainty. This explains why cheap valuation has not attracted capital—the market is pricing in a growth deceleration not yet reflected in forward estimates.
Key Observation: Absent fresh negative developments, and with continued partnership progress (Zegfrovy commercialization), depressed valuation may provide support for medium-term entry points. Near-term, however, trial risk digestion and rating recalibration will require time.